Detail

Basic Information Clinical Results Relationship Graph

GTO ID	GTC2438
Trial ID	NCT04528719
Disease	Respiratory Syncytial Virus Infectious Disease
Altered gene	F
Therapeutic/Target gene	Therapeutic gene
Therapy	mRNA vaccine
Treatment	mRNA-1345
Phase	Phase1
Recruitment status	Active, Not Recruiting
Title	A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Healthy Younger Adults Aged 18 to 49 Years, Women of Child-Bearing Potential Aged 18 to 40 Years, Healthy Older Adults Aged 65 to 79 Years, Japanese Older Adults Aged ≥ 60 Years, and RSV-Seropositive Children Aged 12 to 59 Months
Year	2020
Country	United States
Company sponsor	ModernaTX, Inc.
Other ID(s)	mRNA-1345-P101

Vector information

Vector	lipid nanoparticle

Cohort1: Younger Adults_mRNA-1345_Single injection_dose level 3

Cohort2: Younger Adults_mRNA-1345_Single injection_dose level 4

Cohort3: Younger Adults_mRNA-1345_Single injection_dose level 5

Cohort4: Younger Adults_Placebo_Single injection

Cohort5: Younger Adults_mRNA-1345_three total injections

Administration route	intramuscular injection
Dosage	mRNA-1345, three total injections, 100 μg
Pts	51
Age	Child, Adult, Older_Adult
References	PMID: 38298125 \| 38385566

Cohort6: Younger Adults_Placebo_three total injections

Cohort7: Older Adults_mRNA-1345_dose level 1

Cohort8: Older Adults_mRNA-1345_dose level 2

Cohort9: Older Adults_mRNA-1345_dose level 3

Cohort10: Older Adults_mRNA-1345_dose level 4

Cohort11: Older Adults_mRNA-1345_dose level 5

Cohort12: Older Adults_placebo

Cohort13: Children

Cohort14: Women of Child-Bearing Potential

Cohort15: Japanese Older Adults

Overview of Knowledge Graph